Franchesca D Choi1, Christina N Kraus2, Ashley N Elsensohn2, Sama K Carley2, Larisa M Lehmer2, Rebecca T Nguyen3, Kenneth G Linden4, Jessica Shiu2. 1. Department of Dermatology, University of California, Irvine, California; School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: choi.franchesca@yahoo.com. 2. Department of Dermatology, University of California, Irvine, California. 3. School of Medicine, University of Michigan, Ann Arbor, Michigan. 4. Department of Dermatology, University of California, Irvine, California; Melanoma Center, Chao Family Comprehensive Cancer Center, Irvine, California.
Abstract
BACKGROUND: Immunotherapy using programmed cell death 1 protein (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors has been increasingly reported in a variety of nonmelanoma skin cancers (NMSCs). OBJECTIVE: To analyze the evidence of PD-1 and PD-L1 inhibitors in the treatment of NMSC. METHODS: A primary literature search was conducted with the PubMed, Cochrane Library, EMBASE, Web of Science, and CINAHL databases through October 28, 2018, to include studies on the use of PD-1 or PD-L1 inhibitors in patients for NMSC. Two reviewers independently performed study selection, data extraction, and critical appraisal. RESULTS: This systematic review included 51 articles. The most robust evidence was in the treatment of Merkel cell carcinoma and cutaneous squamous cell carcinomas, as supported by phase 1 and 2 clinical trials. Treatment of basal cell carcinoma, cutaneous sarcoma, sebaceous carcinoma, and malignant peripheral nerve sheath tumor also showed benefit with PD-1/PD-L1 inhibitors, but data are limited. There does not appear to be efficacy for PD-1/PD-L1 inhibitors in cutaneous lymphomas. LIMITATIONS: More investigation is needed to determine the efficacy, tumor responsiveness, and the safety profile of PD-1 and PD-L1 inhibitors in NMSC. CONCLUSION: PD-1 and PD-L1 inhibitors exhibit treatment efficacy in a variety of NMSCs.
BACKGROUND: Immunotherapy using programmed cell death 1 protein (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors has been increasingly reported in a variety of nonmelanoma skin cancers (NMSCs). OBJECTIVE: To analyze the evidence of PD-1 and PD-L1 inhibitors in the treatment of NMSC. METHODS: A primary literature search was conducted with the PubMed, Cochrane Library, EMBASE, Web of Science, and CINAHL databases through October 28, 2018, to include studies on the use of PD-1 or PD-L1 inhibitors in patients for NMSC. Two reviewers independently performed study selection, data extraction, and critical appraisal. RESULTS: This systematic review included 51 articles. The most robust evidence was in the treatment of Merkel cell carcinoma and cutaneous squamous cell carcinomas, as supported by phase 1 and 2 clinical trials. Treatment of basal cell carcinoma, cutaneous sarcoma, sebaceous carcinoma, and malignant peripheral nerve sheath tumor also showed benefit with PD-1/PD-L1 inhibitors, but data are limited. There does not appear to be efficacy for PD-1/PD-L1 inhibitors in cutaneous lymphomas. LIMITATIONS: More investigation is needed to determine the efficacy, tumor responsiveness, and the safety profile of PD-1 and PD-L1 inhibitors in NMSC. CONCLUSION: PD-1 and PD-L1 inhibitors exhibit treatment efficacy in a variety of NMSCs.
Authors: Morgan Guénolé; Paolo Bénigni; Vincent Bourbonne; François Lucia; Delphine Legoupil; Olivier Pradier; Laurent Misery; Arnaud Uguen; Ulrike Schick Journal: J Cancer Res Clin Oncol Date: 2021-06-11 Impact factor: 4.553
Authors: Katherine Given Ligtenberg; Jamie Katy Hu; William Damsky; Kelly Olino; Harriet Kluger; James Clune; Shawn E Cowper; Gauri Panse; Jonathan Leventhal; Sarah A Weiss Journal: JAAD Case Rep Date: 2020-05-17
Authors: Nicholas Frazzette; Alireza Khodadadi-Jamayran; Nicole Doudican; Alexis Santana; Diane Felsen; Anna C Pavlick; Aristotelis Tsirigos; John A Carucci Journal: NPJ Precis Oncol Date: 2020-06-03
Authors: Dulce M Barrios; Mytrang H Do; Gregory S Phillips; Michael A Postow; Tomoko Akaike; Paul Nghiem; Mario E Lacouture Journal: J Am Acad Dermatol Date: 2020-05-24 Impact factor: 11.527